Section 4 of 6
Clinical evidence
137 evidence topics · 18 sources
Study summaries
SGP-005 (Rhine)
Objective
Primary objective of the Phase 3 program
Location and study date
Study dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2025-10-15” |
| Primary completion (estimated) | “2029-03-31” |
| Study completion (estimated) | “2031-03-31” |
| First posted | “2025-10-20” |
Registered recruiting site
| Field | Registry record |
|---|---|
| Facility | “Houston Eye Associates” |
| City | “Houston” |
| State | “Texas” |
| Country | “United States” |
Planned countries, sites, and enrollment timeline
Study design
Registered design
| Design element | Registry record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 3” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Primary purpose | “Treatment” |
| Masking | “Double” |
| Masked roles | “Participant”, “Outcomes Assessor” |
Two identical trials, 1:1 randomization, noninferiority design
Eligibility criteria
Registered inclusion criteria
| Field | Registry record |
|---|---|
| Minimum age | “22 Years” |
| Sex | “All” |
Baseline medication burden permitted
Treatment
Registered arms and interventions
Dose and intended duration of drug delivery
Study outcomes
Rationale for using time-matched mean IOP change from baseline and BCDVA of 20/40 or better as the co-primary endpoints
Registered primary and secondary outcomes
Co-primary and secondary endpoints as described by the sponsor
Rationale for IOP as the efficacy endpoint
Rationale for the BCDVA co-primary endpoint and the noninferiority margin
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Enrollment type | Participants |
|---|---|
| Estimated | “400” |
Analyzed population
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SGP-005 was recruiting at the time of the most recent sponsor update (August 2026), with enrollment completion expected in 2027, 12-month data in 2028, and 24-month data in 2029; no results are available. The comparator is a commercial monofocal IOL plus twice-daily timolol 0.5%, not a prostaglandin analog, sustained-release implant, or MIGS procedure. The registry record lists the BCDVA co-primary endpoint at Month 6, whereas the sponsor's Form 10-K describes it at 12 months. The registry record lists one U.S. site, whereas the sponsor describes approximately 45 sites per trial in the United States, New Zealand, and Asia. The registry record states the study start as October 15, 2025, whereas the Form 10-K states that the Phase 3 trials were initiated in July 2025. No noninferiority margin or statistical analysis plan has been published.
SGP-006 (Rhone)
Objective
Primary objective of the Phase 3 program
Location and study date
Study dates
| Milestone | Registry record |
|---|---|
| Study start (estimated) | “2025-10-28” |
| Primary completion (estimated) | “2029-05-31” |
| Study completion (estimated) | “2031-05-31” |
| First posted | “2025-10-20” |
Registered recruiting site
| Field | Registry record |
|---|---|
| Facility | “R and R Eye Research, LLC” |
| City | “San Antonio” |
| State | “Texas” |
| Country | “United States” |
Planned countries, sites, and enrollment timeline
First randomization and enrollment status
Study design
Registered design
| Design element | Registry record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 3” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Primary purpose | “Treatment” |
| Masking | “Double” |
| Masked roles | “Participant”, “Outcomes Assessor” |
Phase III program design as announced
Protocol changes from the Phase 1/2 trial
Eligibility criteria
Registered inclusion criteria
| Field | Registry record |
|---|---|
| Minimum age | “22 Years” |
| Sex | “All” |
Baseline medication burden permitted
Treatment
Registered arms and interventions
Study outcomes
Rationale for using time-matched mean IOP change from baseline and BCDVA of 20/40 or better as the co-primary endpoints
Registered primary and secondary outcomes
Co-primary and secondary endpoints as announced
Rationale for IOP as the efficacy endpoint
Rationale for the BCDVA co-primary endpoint and the noninferiority margin
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Enrollment type | Participants |
|---|---|
| Estimated | “400” |
Analyzed population
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SGP-006 has the same registered design, eligibility criteria, arms, and outcomes as SGP-005 and was recruiting at the most recent sponsor update, with enrollment completion expected in 2027; no results are available. The registry start date (October 28, 2025) is recorded as estimated, and the record lists one U.S. site. As for SGP-005, the registry lists the BCDVA co-primary endpoint at Month 6 while the sponsor's Form 10-K states 12 months, the active comparator is twice-daily timolol 0.5% with a commercial monofocal IOL, and no noninferiority margin or statistical analysis plan has been published.
SGP-003 (Tigris)
Objective
Location and study date
Study dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-10-13” |
| Primary completion (actual) | “2025-01-31” |
| Study completion (estimated) | “2027-11” |
| Overall status | “Active, not recruiting” |
Countries and enrollment completion
Registered site
| Field | Registry record |
|---|---|
| Facility | “Arizona Advanced Eye Research Institute” |
| City | “Glendale” |
| State | “Arizona” |
| Country | “United States” |
Study design
Registered design
| Design element | Registry record |
|---|---|
| Phase | “Phase 1”, “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Masked roles | “Participant”, “Care Provider”, “Investigator”, “Outcomes Assessor” |
Randomization, washout, and IOP measurement schedule
Eligibility criteria
Registered inclusion criteria
| Field | Registry record |
|---|---|
| Minimum age | “22 Years” |
| Sex | “All” |
Treatment
Registered arms and interventions
Doses, allocation ratio, and concomitant eye drops
Study outcomes
Rationale for using time-matched mean IOP reduction from baseline as the primary endpoint
Registered primary, secondary, and other outcomes
Rationale for IOP as the efficacy endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Enrollment type | Participants |
|---|---|
| Actual | “201” |
Evaluable participants at 12 months
Description of analysis sets
Statistical methods and analysis sets
No evidence found.
Results
Participant disposition
Summary
The registry record lists an actual enrollment of 201 participants, while all company disclosures report 104 randomized participants (78 mcg, n=51; 39 mcg, n=23; timolol control, n=30). The difference may reflect consented participants who did not meet surgical eligibility criteria, but no source reconciles the two counts. At 3 months, medication-free status was reported for 50 evaluable participants in the 78-mcg group. At 12 months, 49 (78 mcg) and 23 (39 mcg) participants were evaluable for medication-free status, and 47 (78 mcg), 21 (39 mcg), and 29 (control) participants were evaluable for IOP at 8 a.m. Reasons for non-evaluability were not reported.
Baseline characteristics
Baseline topical medication use and visual acuity
Baseline demographics and baseline IOP by group
No evidence found.
Efficacy results
Summary: 3-month and 12-month topline results
At 3 months (primary endpoint period), mean IOP reductions from baseline at 8 a.m. were 37% (78 mcg), 36% (39 mcg), and 37% (timolol control); absolute reductions were -9.29 mmHg (8 a.m.) and -9.19 mmHg (10 a.m.) for 78 mcg, -9.64 and -8.70 mmHg for 39 mcg, and -9.63 and -10.24 mmHg for control. No between-group statistical comparison or noninferiority analysis was reported. At 3 months, 49 of 50 (98%) participants in the 78-mcg group and 22 of 23 (96%) in the 39-mcg group were free of topical IOP-lowering medications, and all participants had BCDVA of 20/40 or better.
At 12 months, evaluable participants had mean IOP reductions of 34% (78 mcg, n=47), 42% (39 mcg, n=21), and 35% (control, n=29) at 8 a.m.; 48 of 49 (98%) in the 78-mcg group and 22 of 23 (96%) in the 39-mcg group were free of topical IOP-lowering medications; and 72 of 72 (100%) evaluable BIM-IOL participants had BCDVA of 20/32 or better, with mean BCDVA of 86 letters. Company summaries also describe 97% of treated participants as drop-free at 3 and 12 months. Absolute 12-month IOP values, 10 a.m. percentages, variance estimates, and p values were not published. No peer-reviewed publication or congress abstract with full Phase 1/2 data was identified; the company stated that additional results would be presented at a future medical meeting.
IOP reduction at 3 months: percentage and absolute change
IOP reduction, medication-free status, and visual acuity at 3 months as presented at IGC 2025
IOP reduction, medication-free status, and visual acuity at 12 months
Independent trade-journal summary of Phase 1/2 results
Peer-reviewed publication or congress abstract of Phase 1/2 results
No evidence found.
Health-related quality of life and patient-reported outcomes
Patient-reported outcome results
No evidence found.
Safety results
Adverse event rates and serious events at 3 and 12 months
Most common study-eye adverse events through 3 months (3% or greater in any group)
| Adverse event | 78 mcg, n = 51, n (%) | 39 mcg, n = 23, n (%) | Control, n = 30, n (%) |
|---|---|---|---|
| Eye disorders | “17 (33.3)” | “8 (34.8)” | “9 (30.0)” |
| Iritis | “4 (7.8)” | “1 (4.3)” | “1 (3.3)” |
| Corneal edema | “3 (5.9)” | “2 (8.7)” | “1 (3.3)” |
| Keratitis | “1 (2.0)” | “0” | “1 (3.3)” |
| Eye pruritus | “0” | “0” | “1 (3.3)” |
| Eye inflammation | “3 (5.9)” | “0” | “0” |
| Visual impairment (i.e., halos) | “2 (3.9)” | “0” | “0” |
| Dry eye | “0” | “4 (17.4)” | “1 (3.3)” |
| Visual acuity reduced (BCDVA loss ≥ 10 letters) | “2 (3.9)” | “2 (8.7)” | “2 (6.7)” |
| Corneal defect | “0” | “1 (4.3)” | “0” |
| Meibomian gland dysfunction | “4 (7.8)” | “0” | “2 (6.7)” |
| Anterior capsule contraction | “0” | “1 (4.3)” | “0” |
| Vitreous detachment | “1 (2.0)” | “0” | “1 (3.3)” |
| Pterygium | “0” | “0” | “1 (3.3)” |
| Swelling of eyelid | “0” | “0” | “1 (3.3)” |
| General disorders and conditions | “0” | “0” | “1 (3.3)” |
| Impaired Healing | “0” | “0” | “1 (3.3)” |
| Infections (i.e., conjunctivitis, periorbital cellulitis, hordeolum) | “2 (3.9)” | “1 (4.3)” | “0” |
Severity of cumulative ocular adverse events at 3 months
| Severity | 78 mcg, N = 51, n (%) | 39 mcg, N = 23, n (%) | Control, N = 30, n (%) |
|---|---|---|---|
| Cumulative | “18 (35.3)” | “9 (39.1)” | “10 (33.3)” |
| Mild | “15 (29.4)” | “8 (34.8)” | “8 (26.7)” |
| Severe | “0” | “1 ( 4.3)” | “0” |
Severe adverse event and corneal endothelial cell density
Adverse events by type at 12 months
No evidence found.
Study limitations
Summary
All Phase 1/2 results available as of September 2026 are sponsor-reported topline data from press releases and SEC filings; no peer-reviewed publication, congress abstract, or registry results posting was identified. The trial was not described as powered for noninferiority, and no confidence intervals, p values, or between-group tests were published. Registered enrollment (201) differs from the randomized population (104), and 12-month IOP analyses used evaluable subsets (47 of 51, 21 of 23, and 29 of 30). The 12-month IOP reduction for the 78-mcg dose (34%) was lower than at 3 months (37%) and numerically lower than the 39-mcg dose (42%), while the Form 10-K describes the reduction as sustained at similar rates. The active control was timolol 0.5% twice daily rather than a prostaglandin analog. The drug pads are non-bioerodible and designed for 3 years of delivery; efficacy after drug depletion and retreatment options have not been reported. The sponsor also reported that 30% to 37% of participants were not taking topical IOP-lowering medications at baseline.
SGP-SPEC-004
Objective
Rationale for extended follow-up
“At that time, findings were reviewed, and the decision was made to extend study monitoring through 7 years. This was done to better guide future study design and to provide surgeons with further information on a device that had already generated anecdotal interest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and site
| Field | Registry record |
|---|---|
| Study start (actual) | “2023-03-16” |
| Primary completion (estimated) | “2031-04-14” |
| Study completion (estimated) | “2031-04-14” |
| First submitted | “2025-08-22” |
| Facility | “Centro Oftalmológico Robles” |
| City | “Santa Rosa de Copán” |
| Country | “Honduras” |
Study design
Registered observational design
| Design element | Registry record |
|---|---|
| Study type | “Observational” |
| Observational model | “Cohort” |
| Time perspective | “Prospective” |
| Sampling method | “Non-Probability Sample” |
Protocol amendment, visit schedule, and IOP measurement
“The protocol was amended to include future follow-up visits and the corresponding assessments. Eligible enrollees were reconsented accordingly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For this interim report, postoperative follow-up visits occurred at day 1, week 1, and months 1, 3, 6, 9, 12, 18, 24, 30, and 36.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All scheduled IOP measurements were performed at approximately 8 AM. To minimize bias, IOP was assessed by two observers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Registered eligibility criteria and study population
Exclusion of the participant with preexisting diabetic retinopathy
Treatment
Dose cohorts followed (no new intervention)
| Cohort | Registry arm label |
|---|---|
| Low dose | “Bimatoprost Implant System / IOL Combination Low Dose” |
| Medium dose | “Bimatoprost Implant System / IOL Combination Medium Dose” |
| High dose | “Bimatoprost Implant System / IOL Combination High Dose” |
Study outcomes
Rationale for using the proportion of unmedicated eyes with IOP reduction of 20% or more as the primary endpoint
Registered primary and other outcomes
Rationale for the 20% IOP reduction threshold
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Enrollment type | Participants |
|---|---|
| Actual | “23” |
Description of analysis sets
Per-protocol and intention-to-treat analyses, statistical tests, and handling of rescue medication
“To focus on the effect of the technology on a consistent cohort inclusive of the other 23 enrollees who completed subsequent visits, we primarily implemented a per-protocol approach. An intention-to-treat analysis, including the subject with preexisting diabetic retinopathy, is included in the Supplementary Material.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Paired IOP outcomes were analyzed using the Wilcoxon signed-rank test. Comparisons between mean IOPs across the three treatment arms were conducted via the Kruskal–Wallis test and with mixed model repeated measure analysis. If an ocular antihypertensive medication was reintroduced in a subject during follow-up, the IOP values used for analyses at subsequent visits were carried forward from the last unmedicated IOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Retention through 36 months
“All 23 subjects were retained through the month 30 follow-up visit. Between months 30 and 36, two subjects in the high-dose cohort withdrew. The first subject moved to another country, and the second exited to undergo palliative care in the setting of newly diagnosed pancreatic cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics of the extension cohort
| Characteristic | Data (n = 23) |
|---|---|
| Age, mean years ± SD | “70.5 ± 9.6”View highlighted excerpt for this quote |
| Female, n (%) | “12 (52.2%)”View highlighted excerpt for this quote |
| Hispanic or Latino, n (%) | “23 (100%)”View highlighted excerpt for this quote |
| Primary open-angle glaucoma, n (%) | “23 (100%)”View highlighted excerpt for this quote |
| Ocular hypertension, n (%) | “0 (0%)”View highlighted excerpt for this quote |
| Pre-washout screening IOP, mean mmHg ± SD | “16.5 ± 3.5”View highlighted excerpt for this quote |
| Post-washout baseline IOP, mean mmHg ± SD | “25.1 ± 2.5”View highlighted excerpt for this quote |
| One ocular hypotensive medication, n (%) | “20 (87.0%)”View highlighted excerpt for this quote |
| Two ocular hypotensive medications, n (%) | “1 (4.3%)”View highlighted excerpt for this quote |
| Three ocular hypotensive medications, n (%) | “2 (8.7%)”View highlighted excerpt for this quote |
| Endothelial cell density, mean cells/mm2 ± SD | “2308 ± 223”View highlighted excerpt for this quote |
Efficacy results
Summary: IOP and medication outcomes from month 9 through month 36
In the per-protocol cohort, mean IOP decreased from 25.1 ± 2.5 mmHg at post-washout baseline to 13.8 ± 2.4 mmHg at month 9, 13.9 ± 2.3 mmHg at month 12, 14.5 ± 3.0 mmHg at month 24, and 15.9 ± 2.8 mmHg at month 36 (n=21), corresponding to mean reductions of 44.6%, 44.0%, 41.9%, and 36.7% (p < 0.0001 at each visit). All 21 eyes followed to month 36 maintained an IOP reduction greater than 20%, and 19 of 21 (90.5%) had IOP below 18 mmHg. All 16 participants in the 75 μg and 150 μg cohorts remained drop-free through month 36; one participant in the 300 μg cohort restarted topical medication at month 30, giving 20 of 21 (95.2%) drop-free at 36 months. Month-36 IOP did not differ significantly among dose cohorts (p = 0.50), and the 300 μg cohort (n=5) did not reach statistical significance for IOP reduction from baseline (p = 0.06). The sponsor reported that 4-year follow-up data are expected in the fourth quarter of 2026.
IOP over time, overall per-protocol sample
IOP at month 36 by dose cohort
Medication-free status and IOP targets through month 36
“Through month 24, all study eyes continued to maintain an IOP reduction > 20%, and all but one study eye measured at an IOP of 18 mmHg or less. All 16 subjects in the 75 μg and 150 μg cohorts remained off glaucoma drops through month 36. A single subject in the 300 μg arm required reintroduction of a topical IOP-lowering medication at month 30. Thus, at last follow-up, 95.2% of study eyes (n = 20) remained topical medication-free. All month 36 subjects maintained an IOP reduction > 20% and all but two subjects (90.5%, n = 19) achieved an IOP < 18 mmHg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the aggregate sample, mean percentage IOP reduction from baseline was 36.7 ± 9.4% (p < 0.0001) by month 36.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This model resulted in a two-sided p value of 0.36 for the time in months by treatment interaction, showing no overall difference between groups in IOP change over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
36-month results as reported by the sponsor
36-month results as presented at the Interventional Glaucoma Consortium 2025
Earlier data cut: 18 months presented at ASCRS 2025
Earlier data cut: 18 months presented at Glaucoma 360 2025
Effect of the two withdrawals in the 300 microgram cohort on the month 36 analysis
“Regarding the two 300 μg subjects who dropped out for aforementioned reasons after month 30, one subject had a measured IOP of 11.0 mmHg, while the other’s was 16.5 mmHg at their final study visits. Neither subject required reintroduction of a topical agent prior to dropout. Hence, their dropout may have contributed to statistical underestimation of the 300 μg dose effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Cumulative adverse events through 36 months
Prostaglandin-class effects, implant stability, and serious events
“There were no cases of prostaglandin-associated periorbitopathy, no abnormal eyelash growth, and no cases of iris hyperpigmentation. There were no IOL dislocations, bimatoprost drug pad displacements, explantations, or reports of clinically significant posterior capsule opacification.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No deaths or serious adverse events related to the implant occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corneal endothelial cell density and anterior chamber inflammation
“There was a reduction from a baseline of 2308 ± 223 cells/mm2 to 2068 ± 374 cells/mm2 (− 10.4%) by month 6 and 2013 ± 407 cells/mm2 (− 12.8%) by month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no anterior chamber inflammation observed in any subject’s study eye for the remainder of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor summary of product-related adverse events
Method used for the endothelial cell density measurements
“Although endothelial cell density measurements did not employ a validated reading center methodology, outcomes from automated measurements are reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, corneal endothelial cell count data were not sufficiently reliable as they were derived directly from automated machine output and not verified by a reading center.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
The long-term evidence comes from one sponsor-funded, single-surgeon, single-site cohort of 23 eyes in Honduras, with sequential unmasked dose assignment, no control group, and registration completed retrospectively in September 2025, after the 6-month pilot ended and 36-month follow-up was in progress. All participants were Hispanic or Latino with primary open-angle glaucoma, 87.0% were controlled on one medication before washout, and prior response to topical prostaglandin analogs was required. The study did not include a cataract-surgery-only comparator, although cataract extraction alone lowers IOP by 2 to 4 mmHg in glaucoma populations. Endothelial cell counts were automated without reading-center verification, and specular microscopy stopped after month 12. The authors state that the sponsor participated in design, analysis, and manuscript preparation, and that several authors are SpyGlass employees, consultants, or shareholders. The studied doses (75, 150, and 300 μg) differ from the Phase 3 dose (78 mcg).
Limitations stated by the authors
“This first-in-human study has important limitations, including small sample size, nonrandomized design, and selection of prior prostaglandin analogue responders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This criterion selected for eyes that would be more likely to benefit from the bimatoprost implant, possibly inflating efficacy metrics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As with any investigation that examines a technology paired with cataract extraction, one must consider the standalone 2–4 mmHg reduction achieved by the latter in glaucoma populations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrospective registration of the current study increases risk for bias; outcomes should thus be interpreted cautiously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in the publication
“The sponsor participated in the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, and review and approval of the manuscript.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SGP-SPEC-001
Objective
Publication aim
“This study aimed to explore the safety and efficacy of sustained release bimatoprost implant with SpyGlass intraocular lens (SpyGlass Pharma, Inc., Aliso Viejo, CA, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A placebo arm was not included because the current study was designed as a pilot to help guide dose selection for future research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and site
| Field | Registry record |
|---|---|
| Study start (actual) | “2022-04-21” |
| Primary completion (actual) | “2022-12-13” |
| Study completion (actual) | “2022-12-13” |
| First submitted | “2025-08-22” |
| Facility | “Centro Oftalmológico Robles” |
| City | “Santa Rosa de Copán” |
| Country | “Honduras” |
Enrollment period and ethics approval
“The first patient was consented in April 2022, and the completion date of this initial pilot was December 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This nonrandomized, prospective, proof-of-concept interventional study was approved by the National Health Research Ethics Committee in El Salvador (CNEIS/2022/01H).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Registered design
| Design element | Registry record |
|---|---|
| Phase | “Not Applicable” |
| Allocation | “Non-Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Single” |
| Masked roles | “Outcomes Assessor” |
Allocation and masking as published
“Participants were sequentially assigned by the local investigator (author MR) to receive either the low configuration (75 μg bimatoprost), medium configuration (150 μg), or high configuration (300 μg) of the product in a 1:1:1 allocation ratio. Neither subjects nor investigators were masked to assignments. Only one eye per subject was designated for treatment in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Treatment
Implant configuration and surgical procedure
“The studied drug delivery system consists of two silicone molded pads attached to an IOL (defined as the bimatoprost implant system). Each pad sits at the optic–haptic junction, contains a multiyear bimatoprost load, and delivers slow, continuous elution of bimatoprost with a near-zero-order delivery profile. Studied drug content selections include 75 μg, 150 μg, and 300 μg of bimatoprost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The postoperative regimen included a weekly taper of topical steroid/antibiotic combination from Q4H to Q6H to Q8H over a 3-week period. IOP-lowering drops were not reintroduced unless clinically necessary.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using the proportion of unmedicated eyes with IOP reduction of 20% or more at month 6 as the primary endpoint
Registered primary and secondary outcomes
Primary endpoint as published
“The primary endpoint was the proportion of unmedicated eyes with IOP reduction > 20% from baseline at month 6 and onward. Secondary outcomes included adverse events, mean changes in IOP, and mean changes in glaucoma medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the 20% IOP reduction threshold
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants
“The enrollment target was set at up to 30 subjects. Sample size was not calculated to attain pre-determined power for specified assumptions and type I error. Instead, the sample size was determined on the basis of ethical considerations, to adequately characterize safety across the three doses, and to obtain initial estimates of mean change-from-baseline IOPs with corresponding standard deviations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Enrollment type | Participants |
|---|---|
| Actual | “24” |
Description of analysis sets
Analysis populations and significance threshold
“The statistical significance threshold was set at p < 0.05. Data were analyzed both on a per-protocol basis and with intention-to-treat analysis, by a trained statistician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When compared to the intention-to-treat IOP analysis through 6 months, outcomes were similar (Supplemental Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, enrollment, and protocol deviation
“A total of 29 subjects were consented for the study from April through June 2022 (Fig. 2). Of those, four subjects failed either inclusion or exclusion criteria prior to surgery, and one withdrew consent prior to any study procedures being performed. The remaining 24 enrollees all received surgical interventions corresponding to their sequential assignments. Eight subjects per group received the low, medium, and high dose implants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No enrollees dropped out during the first 6 months of follow-up. At month 3 it was discovered that a single subject in the high dose implant cohort had preexisting diabetic retinopathy. This subject should have failed eligibility criteria prior to surgery (Table 1) but was followed for safety until referral to the retina clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics as published
“Mean age was 70.5 ± 9.6 years, with a near-equal gender ratio. All subjects were of Hispanic/Latino ethnicity and Caucasian race, and all were diagnosed with primary open-angle glaucoma (POAG) with a mean vertical cup-to-disc ratio of 0.6 ± 0.2. Median BCDVA prior to cataract surgery was 20/50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Target pressures for most subjects were achieved preoperatively on a single ocular hypotensive agent (n = 20, 87.0%), while the remainder required two or three. Prior to medication washout, mean IOP was 16.5 ± 3.5 mmHg. Post-washout mean IOP was 25.1 ± 2.5 mmHg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint at month 6
“By week 1, all groups achieved mean IOP reductions exceeding 40% (p < 0.05 all).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At month 6, every individual study eye achieved an unmedicated IOP reduction ≥ 20% versus baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IOP at months 3 and 6 by dose cohort (per-protocol)
Change from baseline and between-cohort comparison at months 3 and 6
| Measure | Month 3 | Month 6 |
|---|---|---|
| Overall CFB IOP, mean mmHg ± SD | “− 11.6 ± 2.8”View highlighted excerpt for this quote | “− 11.3 ± 3.1”View highlighted excerpt for this quote |
| p value (CFB = 0) | “< 0.0001”View highlighted excerpt for this quote | “< 0.0001”View highlighted excerpt for this quote |
| p value (CFB among Tx) | “0.65”View highlighted excerpt for this quote | “0.72”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Intraoperative and early postoperative findings
“All procedures were uncomplicated except for a single subject in the low dose cohort who experienced mild iris prolapse into the main incision after anterior chamber overinflation; the iris appearance had normalized without sequelae on scheduled follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regarding postoperative changes, mild corneal edema was noted in 13 study eyes at day 1 (56.5%). This decreased to a single eye (4.3%) by week 1. At all subsequent visits, no corneal edema was reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At postoperative month 1, only two subjects (8.7%) had faint anterior chamber cells in their study eyes; all other study eyes were clear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transient visual acuity loss at month 1
“Temporary loss of ≥ 2 Snellen lines occurred in the study eyes of three subjects, each at the month 1 visit. Two were attributed to ocular surface disease and responded to topical drops by subsequent visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The third instance had no associated ocular findings and self-resolved by the next visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
SGP-SPEC-001 was a 6-month, single-site, nonrandomized, unmasked dose-exploration pilot in 24 participants, registered on ClinicalTrials.gov in August to September 2025, almost 3 years after its December 2022 completion. The authors did not calculate sample size for statistical power, and one enrolled participant with preexisting diabetic retinopathy should have been excluded before surgery. Only prior responders to topical prostaglandin analogs were eligible, all participants had primary open-angle glaucoma (none had ocular hypertension), and the IOL power range was limited to 19.0 to 25.0 D. No dose-response relationship was observed: month-6 IOP change did not differ among cohorts (p = 0.72), and the doses tested (75, 150, 300 μg) are not the Phase 3 dose (78 mcg). The registry describes the trial as "controlled," although no control group was enrolled.
Limitations stated by the authors
“A small, nonrandomized sample with no control group greatly limits validity and may have contributed to underestimation of adverse effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The single-site design with a sample comprised entirely of white Latino patients with POAG further limits generalizability to wider populations. Procedures were performed by a single ophthalmologist; given that cataract surgery approaches vary, other operators may realize challenges with a new product.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most subjects required only a single glaucoma medication prior to washout; as such, it is less clear how this product would perform for more recalcitrant glaucomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote